Acmopatide Trial Shows Gains in Type 1 Diabetes

A Phase 2 study found acmopatide improved blood sugar control and body weight in adults with type 1 diabetes and overweight or obesity.

Updated on Nov. 6, 2026 in Diabetes

Acmopatide Trial Shows Gains in Type 1 Diabetes

A Phase 2 randomized, placebo-controlled trial tested acmopatide added to standard insulin therapy in 111 patients with type 1 diabetes and a BMI of at least 27 kg/m2. The drug improved glycemic control, body weight, and insulin requirements compared with placebo.

Why it matters

Many people with type 1 diabetes struggle to reach glycemic targets, face acute metabolic risk, and increasingly have overweight or obesity. Results from this trial suggest a possible added option for a group with limited choices.

The Phase 2 trial enrolled 111 patients, with HbA1C at week 16 falling -0.59% in the 4.1 mg arm versus -0.25% in placebo, and 55.6% of that arm reaching a 7.0% HbA1C reduction. Outcomes beyond week 16 and the drug's performance in larger populations remain unreported.

The players

University of North Carolina at Chapel Hill

A public research university whose investigators led the trial, one of the most prominent public universities in the United States.

The details

Patients were randomly assigned to one of three acmopatide doses (1.8 mg, 4.1 mg, or 6.6 mg) or placebo, with the primary end point being percent change in HbA1C at week 16. No deaths, severe hypoglycemia events, or diabetic ketoacidosis events occurred during the study.

Primary end point measured at week 16 of the trial.

Health Landscape

Type 1 diabetes treatment has long centered on insulin replacement, so an add-on drug tested alongside standard insulin therapy represents an extension of that framework. The trial's results will matter most if confirmed in larger, longer studies that test whether such add-ons can meaningfully change the glycemic and weight challenges that insulin alone does not fully address.

For people with type 1 diabetes who also carry extra weight, an add-on therapy that lowers blood sugar and body weight could eventually offer another tool beyond insulin. However, this is an early-stage trial, and patients should not change their treatment based on these results.

The takeaway

Early trial results show acmopatide can work alongside insulin to improve glucose control and reduce weight in type 1 diabetes. Larger and longer studies will be needed before the approach can be considered for clinical use.